Amgen Inc., Eli Lilly and Company, and Hikma Pharmaceuticals PLC were Dominating Saudi Arabia Osteoporosis Drugs Market in 2021

Saudi Arabia Osteoporosis Drugs Market is expected to grow with the CAGR of 2.9% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/saudi-arabia-osteoporosis-drug-market

The market osteoporosis drugs have witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Saudi Arabia osteoporosis drugs market are introducing strong range of products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance-

  • In April 2019, Amgen Inc. launched Evenity for high-risk Osteoporosis. This launch helped the company to grow its overall osteoporosis market and meet the demands of their customers.

Amgen Inc. is the dominating player in Saudi Arabia osteoporosis drugs market. The other key players existing in the market includes Eli Lilly and Company, Novartis AG, Tabuk pharmaceuticals, SPIMACO, Hikma Pharmaceuticals PLC, Pfizer Inc., Merck KGaA, Apotex Inc., ABIOGEN PHARMA S.p.A., Sudair Pharma, tadawipharma., Fresenius SE & Co. KGaA, Hayat Pharmaceutical Industries Co. PLC and SAJA Pharmaceuticals among others.

Saudi Arabia Osteoporosis Drugs Market Amgen Inc.

Amgen Inc. is headquartered in California, United States. The company was established in 1980. The company is focused in transforming science and biotechnology into therapies that have the power to restore health or save lives. The company is dealing in only one business segment that is human therapeutics. The company has product categories including Prolia/XGEVA, Otezla, Aranesp, KYPROLIS, Repatha, Vectibix, Parsabiv, BLINCYTO, Aimovig, EVENITY, IMLYGIC in which the market focused categories are Prolia/XGEVA, and EVENITY.

The company is engaged in continuous development of osteoporosis drugs.

For instance,

  • In April 2019, Amgen Inc. launched Evenity for high-risk Osteoporosis. This launch helped the company to grow its overall osteoporosis market and meet the demands of their customers

The company has wide presence across Asia-Pacific, Europe, North America, South America and Middle East & Africa. The company has various subsidiaries like Five Prime Therapeutics Inc. (U.S.), Immunex (U.S.), Amgen Switzerland AG (Switzerland), Amgen Australia Pty Limited (Australia) among others.

Eli Lilly and Company

Eli Lilly and Company is headquartered in Indiana, United States and was founded in 1876. The company is focused in manufacturing pharmaceutical product and to create medicines that make life better for people around the world. The company is dealing in one business segment, that is, human pharmaceutical products. the company has product categories including diabetes products, oncology products, immunology products, neuroscience products, and other therapies in which the market focused category is other therapies.

The company has wide presence across North America, South America, Europe, Middle East and Africa, Asia-Pacific. The company also has various subsidiary companies such AME Torreview LLC (Delaware), Andean Technical Operations Center (Peru), Applied Molecular Evolution, Inc. (Delaware), Avid Radiopharmaceuticals, Inc. (Pennsylvania) among others.

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC has its headquarters in Amman, Jordan and was founded in 1978. The company is focused in developing, manufacturing and marketing a broad range of branded and non-branded generic medicines. The company has business segment such as Injectables, Generics in which the market focused segment is Generics.This company has product categories including US products, MENA products, Europe products, generic, and branded in which the market focused categories are MENA products and generic.

The company is engaged in continuous development of osteoporosis drugs and related products.

  • In September 2021, Hikma Pharmaceuticals PLC announced that it has agreed to acquire Custopharm Inc. to grow the injectable and generic business segments of the company. Custopharm has received 13 US FDA approvals, with four first-to-market Abbreviated New Drug Application (ANDA) approvals - including one with Competitive Generic Therapy (CGT) designation - and one novel 505(b)(2) NDA approval.  This acquisition helped the company to increase its product portfolio and to further grow the overall revenue of the company

The company has wide presence across North America, Europe, Middle East and Africa.